News



Back


27/01/2023
Amolyt Pharma Announces Research Agreement and Licensing Option with XOMA

Amolyt to advance pre-clinical development of anti-PTHR1 monoclonal antibodies as potential treatments of primary hyperparathyroidism (PHPT) and humoral hypercalcemia of malignancy (HHM)

Amolyt has obtained the option to license one or more candidates from XOMA for further clinical development worldwide

PHPT and HHM are rare endocrine diseases with high unmet needs and these candidates from XOMA represent a natural expansion of Amolyt’s current development pipeline


LYON, France, and Cambridge, MA, January 24, 2023 - Amolyt Pharma (“Amolyt,” “Amolyt Pharma” or the “Company”), a global company specialized in developing innovative therapies for rare endocrine and related diseases, today announced that the Company has entered into a research agreement and licensing option with XOMA Corporation (“XOMA”) for the pre-clinical evaluation of a select set of monoclonal antibodies that arose from XOMA’s legacy discovery efforts as potential treatments for primary hyperparathyroidism (“PHPT”) and humoral hypercalcemia of malignancy (“HHM”). Amolyt has the option to license one or more of these candidates from XOMA for further clinical development worldwide.

Both PHPT and HHM are rare endocrine diseases with high unmet needs and a common target, the parathyroid hormone 1 receptor (“PTH1R”), and are characterized by the hypersecretion of parathyroid hormone (“PTH”) and parathyroid hormone-related peptide (“PTHrP”), respectively, resulting in continuous stimulation of the PTH1R, leading to bone loss, hypercalcemia and hypophosphatemia. The objective of the research agreement is to test the anti-PTH1R antibodies in relevant animal disease models with the aim of selecting a candidate that can successfully halt the over-stimulation of the PTH1R caused by excess PTH and PTHrP and eliminate the debilitating symptoms and serious complications associated with PHPT and HHM.

“We are continuing to build our portfolio for rare endocrine and related diseases while moving, in parallel, our lead program for hypoparathyroidism into a pivotal trial. This new program for primary hyperparathyroidism and humoral hypercalcemia of malignancy represents a natural expansion of our pipeline and leverages our clinical expertise in the field of calcium and bone metabolism and in the biology of parathyroid hormone and its receptor,” stated Thierry Abribat, Ph.D., chief executive officer of Amolyt Pharma.

“We look forward to advancing this pre-clinical work and, if successful, entering into a license agreement with XOMA in order to bring the program to patients, to expand our development pipeline and to establish more opportunities for long-term value creation,” Dr. Abribat concluded.

Brad Sitko, chief investment officer of XOMA, added, “Given Amolyt’s established expertise in rare endocrine disorders, and specifically diseases stemming from dysregulation of PTH, we believe they are a great partner to advance the development of these promising antibodies. We look forward to watching Amolyt’s progress, as PHPT and HHM patients are underserved by current standards of care.”
  
   


Download the pdf file





X

X